Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Analysts' ratings for Gilead Sciences (NASDAQ:GILD) over the last quarter vary from bullish to bearish, as provided by 15 analysts. The following table encapsulates their recent ratings ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GILD ...

Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

In the past 60 days, estimates for Gilead’s earnings per share have increased from $7.53 to $7.87 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.76 ...

In the past 60 days, estimates for Gilead’s earnings per share have increased from $7.53 to $7.87 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.76 ...